Merck Life Science in the news

Merck is offering a summer 2027 Regulatory Planning and Publishing internship in Rahway, NJ, for undergraduates receiving Pell grants.

Merck opened a new center in Daejeon for small-scale customized bioprocess materials, supporting customers in process development before large-scale production.

Merck Life Science is investing €13 million to expand its Bengaluru manufacturing site for biological buffers and other critical materials, strengthening its regional supply chain in India and Asia-Pacific.

Bio-Techne's shareholders approved its acquisition by Merck KGaA, with the U.S. antitrust waiting period expired, and completion anticipated by early 2027.

Merck Life Science appointed Christiaan Veltink as Head of HR Business & Enabling Functions, bringing 20 years of diverse HR and business experience.

Merck expanded its Jigani facility in Bengaluru to boost local manufacturing of life science materials for India and the Asia-Pacific region with a ‑13 million investment.

Merck invested 13 million euros to expand its life science manufacturing facility in Bengaluru, enhancing local production of critical materials for the life sciences sector in India and Asia-Pacific.

Merck expanded its Bengaluru manufacturing hub with a  13 million investment to increase local production of critical life science materials, including biological buffers, for the Indian and Asia-Pacific markets.

Merck Life Science is expanding its Singapore BioReliance laboratory to offer advanced analytical and biosafety testing services for biopharmaceutical companies in the Asia-Pacific region.

Merck expanded its biosafety testing laboratory in Singapore to offer advanced analytical and biosafety testing services across the Asia Pacific region, including Cell Line Characterization and GMP next-generation sequencing.

Merck KGaA is preparing to issue ․40 million in tariff refunds to its life science customers through 2026, following a US Supreme Court decision.

Merck KGaA increased its profit outlook for 2026, driven by strong demand in its Life Science and Electronics divisions, and reported better-than-expected quarterly results.

Merck KGaA increased its 2026 profit outlook and beat quarterly estimates, driven by strong demand in its semiconductor and life science businesses, including a major acquisition in the latter.

Merck KGaA increased its profit outlook for 2026 and reported better-than-expected quarterly results, driven by strong performance in its Life Science and Electronics sectors and a major acquisition.

Merck KGaA raised its full-year earnings and sales guidance due to strong lab-equipment business performance and demand for AI chip production materials.

Merck Germany surpasses Q2 expectations, raises full-year profit guidance driven by strong life sciences and electronics performance, with new CEO Kai Beckmann's acquisition strategies and AI-related demand contributing to growth.

Merck KGaA awaits its half-year results in August, balancing recovery in Life Science and growth in Electronics with patent challenges in Healthcare.

Merck is investing 25 million euros to expand its biopharmaceutical testing center in Darmstadt, Germany, to enhance its capabilities in drug and active ingredient release for biological medicines.

Merck is presented as a leading employer in Life Science, offering diverse career paths, stability, and significant investment in research and development across its Life Science, Healthcare, and Electronics sectors.

Merck is acquiring Bio-Techne for $11.3 billion to strengthen its life science business in cell and gene therapies and precision diagnostics.